↓ Skip to main content

Drug Discovery from Mother Nature

Overview of attention for book
Attention for Chapter 16: Deguelin and Its Role in Chronic Diseases
Altmetric Badge

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Deguelin and Its Role in Chronic Diseases
Chapter number 16
Book title
Drug Discovery from Mother Nature
Published in
Advances in experimental medicine and biology, October 2016
DOI 10.1007/978-3-319-41342-6_16
Pubmed ID
Book ISBNs
978-3-31-941341-9, 978-3-31-941342-6
Authors

Jonathan Boyd, Alice Han

Editors

Subash Chandra Gupta, Sahdeo Prasad, Bharat B. Aggarwal

Abstract

Deguelin is one of four major naturally occurring rotenoids isolated from root extracts and is best recognized as a NADH: ubiquinone oxidoreductase (complex I) inhibitor, resulting in significant alterations in mitochondrial function. Deguelin has also been implicated as a regulator of apoptosis through signaling pathways, such as the (PI3K)/Akt pathway, as well as an initiator of cell cycle arrest. Consequently, this compound has accrued great interest as a potential chemopreventive and chemotherapeutic. Additionally, deguelin exposure has been linked to Parkinson's disease (PD). PD is a neurodegenerative disorder, characterized by a substantial loss of dopaminergic neurons in the substantia nigra, as well the manifestation of symptoms such as bradykinesia, rigidity, and rest tremor. While exploring the genetic impact of PD is imperative, environmental factors, such as exposure to pesticides, herbicides, and insecticides, have also been connected to the development of PD. The etiology and pathogenesis of PD are yet to be fully understood and elucidated, but mitochondrial dysfunction is gaining recognition as a molecular hallmark of PD. In fact, deguelin has been reported to elicit PD-like symptoms (degeneration of the dopaminergic pathway) in rats administered with deguelin (6 mg/kg/day for 6 days), possibly through the inhibition of mitochondrial complex I. Further research investigating the mechanisms by which deguelin inhibits central cellular processes is essential in order to advance any prospective research addressing potential applications and risks of deguelin.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 20%
Student > Bachelor 6 17%
Researcher 5 14%
Student > Doctoral Student 2 6%
Student > Master 2 6%
Other 2 6%
Unknown 11 31%
Readers by discipline Count As %
Medicine and Dentistry 5 14%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Biochemistry, Genetics and Molecular Biology 3 9%
Agricultural and Biological Sciences 2 6%
Neuroscience 2 6%
Other 6 17%
Unknown 14 40%